A study using albino cane toads with edited genes challenges the belief that albino wildlife is rare because it’s more ...

Ineos is in negotiations with its partner, the Chinese state-owned oil and chemical company Sinopec, to exit their ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Scientists at St. Jude Children's Research Hospital and Northwestern University identified a previously unknown treatment ...

Intellia Therapeutics (NASDAQ: NTLA) underwent analysis by 21 analysts in the last quarter, revealing a spectrum of ...

In a 15-patient, Phase 1 one, first-in-human trial, a one-time, CRISPR-Cas9 gene-editing therapy safely reduced LDL ...

CTX310 showed promising safety and efficacy in a small Phase I trial, according to data presented at the American Heart ...

A statin isn’t the only answer anymore to lowering cholesterol. The lipid-reducing medicines, among the most widely prescribed drugs in the U.S., have been a mainstay of heart-disease prevention and ...

One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend ...

From revolutionary CRISPR treatment to heavy drinking dangers, here's what you need to know about the latest health research.

In a world-first human trial, Australian researchers have achieved a major milestone in heart disease prevention with a new ...

ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions ('Dyadic'), a global ...